PSC code
HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- PSC code
- AN13
- Latest action
- Oct 19, 2026
Fewer than the minimum comparable awards under this PSC code.
Largest awards under this code
| Award | Contractor | Agency | Place | First action | Current value |
|---|---|---|---|---|---|
| HHSO100201700016C IGF::OT::IGF | REGENERON PHARMACEUTICALS INC | Department of Health and Human Services | NY | Sep 28, 2017 | $973,560,407 |
| 75A50122C00065 TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | AMGEN USA INC | Department of Health and Human Services | CA | Sep 28, 2022 | $839,875,190 |
| 75A50118C00019 PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | SIGA TECHNOLOGIES, INC. | Department of Health and Human Services | OR | Sep 10, 2018 | $626,506,870 |
| HHSO100201700020C IGF::OT::IGF - REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARD | REGENERON PHARMACEUTICALS INC | Department of Health and Human Services | NY | Sep 21, 2017 | $278,844,172 |
| HHSO100200900106C BIOMEDICAL (ADVANCED) | PROTEIN SCIENCES CORP | Department of Health and Human Services | CT | Jun 21, 2009 | $262,590,394 |
| HHSO100201600009C THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDS FROM CLIN 0011 (OPTION 10) AND UPDATE FAR & HHSAR CLAUSES PER EXECUTIVE ORDER AND FAR/HHSAR CLASS DEVIATIONS | CERUS CORPORATION | Department of Health and Human Services | CA | May 18, 2026 | $197,476,020 |
| HHSO100201600038C IGF::OT::IGF HOFFMANN-LAROCHE INC. | HOFFMANN-LA ROCHE INC. | Department of Health and Human Services | NJ | Sep 15, 2016 | $183,844,128 |
| 75A50126C00004 LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS. | SHIONOGI INC | Department of Health and Human Services | NJ | Apr 6, 2026 | $156,103,541 |
| 75A50122C00076 THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | CA | Sep 28, 2022 | $155,212,688 |
| 75A50119C00007 THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES CANCELING YEAR FUNDS FROM REQUISITION OS256610 IN THE AMOUNT OF (-$615,177.10) FROM CLIN0006 AND FROM REQUISITION OS257789 IN THE AMOUNT OF (-$222.20) FROM CLIN00001. | VENATORX PHARMACEUTICALS INC | Department of Health and Human Services | PA | May 26, 2026 | $131,756,814 |
| 75A50122C00031 ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+ | CROSSJECT SA | Department of Health and Human Services | — | Jun 9, 2022 | $108,841,769 |
| HHSO100201600002C IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | Department of Health and Human Services | — | Apr 19, 2016 | $108,445,187 |
| HHSO100201300021C IGF::OT::IGF FOR OTHER FUNCTIONSCELLPHIRE | CELLPHIRE, INC. | Department of Health and Human Services | MD | Sep 19, 2013 | $108,429,753 |
| 75A50123C00056 ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA. | MODEX THERAPEUTICS, INC | Department of Health and Human Services | MA | Sep 27, 2023 | $103,516,903 |
| 75N91022F00001 TASK ORDER 1A: PROJECT KICK-OFF MEETING AND TASK ORDER 2A: CTSU CORE SUPPORT SERVICES & THE CTSU ENTERPRISE OF SYSTEMS; CANCER TRIALS SUPPORT UNIT (CTSU) IDIQ | WESTAT, INC. | Department of Health and Human Services | MD | Jul 25, 2022 | $98,259,375 |
| HHSO100201500029C THE PURPOSE OF MODIFICATION P00014 IS TO DE-OBLIGATE CANCELING FUNDS | PFIZER INC | Department of Health and Human Services | — | May 12, 2026 | $93,359,027 |
| 75A50119C00022 THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 6. | PUBLIC HEALTH VACCINES LLC | Department of Health and Human Services | MA | Jun 8, 2026 | $89,026,883 |
| 75A50123C00035 ADD CLIN 0014 AND FUND $6,500,205.00, REVISE CLINS POP FOR STANDARDIZATION TO DECEMBER 27, 2027, ASSIGN ALT COR AND INCORPORATE MANDATORY CLAUSES AS DIRECTED BY EXECUTIVE ORDER 14398. | GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC. | Department of Health and Human Services | NY | Jun 8, 2026 | $70,479,398 |
| 75A50122C00046 ABBOTT: TO CONDUCT CLINICAL TRAINING AND VALIDATION STUDIES TO SUPPORT A FUTURE FDA MARKETING APPLICATION WITH AN EXPANDED INDICATION FOR USE OF THE ABBOTT TBI TEST ? TO AID IN THE DIAGNOSIS OF TRAUMATIC BRAIN INJURY IN ADULTS AND PEDIATRIC PATIENTS. | ABBOTT LABORATORIES | Department of Health and Human Services | IL | Sep 21, 2022 | $65,469,511 |
| HHSO10033001T IGF::OT::IGF | CANGENE CORPORATION | Department of Health and Human Services | — | Sep 16, 2013 | $63,304,734 |
| 75A50124C00052 THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND | 4J THERAPEUTICS INC | Department of Health and Human Services | CA | Sep 18, 2024 | $63,083,814 |
| 75A50118C00024 UPDATE INDIRECT RATES AND FAR & HHSAR CLAUSES ON CONTRACT | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | CA | May 7, 2026 | $56,704,950 |
| 75A50118C00012 JANSSEN - TPOM OT AGREEMENT | JANSSEN RESEARCH & DEVELOPMENT, LLC | Department of Health and Human Services | NJ | Sep 21, 2018 | $55,960,066 |
| 75N91021C00009 CLINICAL TRIALS AND INFORMATION MANAGEMENT SUPPORT | THE EMMES COMPANY, LLC | Department of Health and Human Services | MD | Apr 6, 2021 | $54,415,311 |
| 75N91022C00013 CLINICAL TRIALS MONITORING SERVICE | THERADEX SYSTEMS, INC. | Department of Health and Human Services | NJ | Apr 27, 2026 | $49,717,754 |
Related records
Derived from awards these records share, ordered by how many.
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals cover awards where the government recorded this PSC code. Codes are taken as reported; awards are never reclassified into a different code.
- 1Awards are grouped by the PSC code the government recorded on the award, taken from USAspending.gov and last refreshed Oct 21, 2026. Miscoded awards stay miscoded here; we do not reassign codes.